Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call March 10, 2026 4:30 PM EDT
Company Participants
Punit Dhillon – President, CEO, Principal Accounting Officer & Director
Christopher Twitty – Chief Scientific Officer
Tu Diep – Chief Operating Officer
Conference Call Participants
Jay Olson – Oppenheimer & Co. Inc., Research Division
Edward Tenthoff – Piper Sandler & Co., Research Division
Michael DiFiore – Evercore ISI Institutional Equities, Research Division
Tsan-Yu Hsieh – William Blair & Company L.L.C., Research Division
Gum-Ming Lowe – Craig-Hallum Capital Group LLC, Research Division
Presentation
Operator
Good afternoon, and thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Skye Bioscience 2025 Fourth Quarter Financial Results and Business Update Call. [Operator Instructions] Before we begin, please note that today’s discussion includes forward-looking statements subject to risks and uncertainties described in Skye’s SEC filings. Actual results may differ materially. Thank you. And I would now like to turn the conference over to Punit Dhillon, Chief Executive Officer. You may begin.
Punit Dhillon
President, CEO, Principal Accounting Officer & Director
Good afternoon, everyone. Thank you for joining us. I’ll start with what we’ve accomplished since our Q3 update. CBeyond established a potential path for nimacimab alongside existing incretin therapies with additive weight loss, encouraging durability and favorable tolerability. At the same time, we strengthened the plan around the signal with 52-week combination data and a clear high-dose rationale and as well as a feasible cutaneous or subcutaneous path for delivery. And we’ve continued to work on the regulatory alignment and target product profile. In short, we’ve moved from a promising signal to a more coherent development case. And that is the backdrop for the next question. What has objectively changed over the last 2 years?
Read the full article here